Form 4: Aptose Biosciences Ex-Director Sells Shares in Acquisition

Former Aptose Biosciences director Mark D. Vincent has disposed of common shares and exercised stock options as part of a business arrangement agreement leading to the company's acquisition.

Summary

• Mark D. Vincent, a former director of Aptose Biosciences Inc., reported transactions involving the disposal of common shares and the exercise of stock options.
• These transactions occurred on June 30, 2026, and are part of a business arrangement agreement for the acquisition of Aptose Biosciences Inc. by a subsidiary of Hammi Pharmaceuticals Co. Ltd.
• The acquisition price was C$2.41 per share, which converted to US$1.72 per share based on an exchange rate of C$1.4 = US$1.00.
• Vincent disposed of 14 common shares at US$1.72 per share.
• Several stock options with varying exercise prices were exercised, including options with exercise prices of $1.97, $0.66, $1.39, $5.15, $6.91, $1.91, $1.14, $1.03, $2.64, and $4.38.
• The total number of shares underlying these exercised options amounts to 402,333.
• The filing notes that option prices and amounts are subject to adjustment due to previous reverse stock splits.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on transactions related to a completed acquisition rather than new operational or financial performance updates. The details provided are factual disclosures of insider activity during the acquisition process.

Positives

• The acquisition by Hammi Pharmaceuticals Co. Ltd. provides a defined exit for shareholders at C$2.41 per share.
• The transaction is approved by the issuer's board, shareholders, and the court, indicating a structured and agreed-upon process.

Negatives

• The filing details the disposal of securities by a former director, which can sometimes be perceived negatively by the market, although in this context it's tied to an acquisition.
• The exercise prices of some stock options are significantly higher than the acquisition price per share (e.g., $6.91, $5.15), suggesting those options may not have been exercised profitably in the context of the acquisition price.

Risks

• The filing mentions that option prices and amounts are subject to adjustment due to previous reverse stock splits, which could impact the final value of exercised options.
• The acquisition is subject to the terms of a business arrangement agreement, implying potential complexities or conditions that need to be met.

Future Outlook

The filing primarily reports past transactions related to an acquisition, rather than providing forward-looking guidance for a continuing entity. The future outlook is now tied to the acquiring company, Hammi Pharmaceuticals Co. Ltd.

Management Comments

• Explanation of Responses: 1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
• Explanation of Responses: 2. Converted from Canadian price of C$2.41 per share using exchange rate of C$1.4 = US$1.00.
• Explanation of Responses: 3. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
• Remarks: TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/25/2025 AND 1:15 REVERSE SPLIT ON 6/6/2023

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. In this case, the transactions are directly linked to a change of control event (acquisition), which is a significant development for any biotechnology company, often driven by pipeline progress, strategic partnerships, or market consolidation.

Management Changes

Stakeholder Impact

• Shareholders: The acquisition provides an exit at C$2.41 per share, as approved by shareholders.
• Former Management/Directors: Mark D. Vincent has completed transactions related to his former role as director in conjunction with the acquisition.
• Employees: The acquisition by Hammi Pharmaceuticals may lead to changes in employment status or roles for Aptose Biosciences employees.

Next Steps

• The acquisition of Aptose Biosciences Inc. by a subsidiary of Hammi Pharmaceuticals Co. Ltd. is complete.
• Further actions or reporting would likely be under the Hammi Pharmaceuticals umbrella or through delisting notices for Aptose Biosciences.

Key Dates

Keywords

Aptose Biosciences, SEC Form 4, Insider Trading, Stock Options, Acquisition, Hammi Pharmaceuticals, Beneficial Ownership, Vincent Mark D., Director Transactions